MEET
Upneeq®
Upneeq® is the only FDA-approved prescription eye drop for low-lying eyelids, also known as acquired ptosis, that lifts your upper eyelids to open your eyes. Upneeq® works by stimulating the contraction and elevation of eyelids by activating receptors in the muscles of the upper eye lid.
If your eyelids look low, tired or sleepy, you may have a condition called acquired blepharoptosis, (also known as acquired ptosis or low-lying lids). This is a common medical condition that can develop later in life. It affects adults of all ages, but occurs more often in older adults. It usually occurs when the muscles in the eyelid stretch and weaken which leads to upper eyelid drooping. It may be caused by other issues, such as cataract surgery, wearing contact lenses, or an underlying medical condition. It may also be a sign of a more serious medical condition.
WHAT IS UPNEEQ®?
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eye drop used to treat acquired blepharoptosis (low-lying lids) in adults. Non-surgical lid-lift for adults who want a brighter, more awake, younger looking face.
Upneeq® Before & After
REPORTED BENEFITS
+ Lifts eyelids quickly
+ Significantly improves upper field of vision
+ Lessens eye redness
Apply one drop of Upneeq® per eye, once a day. You’ll see a visible difference in as little as two hours.
This was true for most patients in clinical trials. 84% of patients had some form of improvement in 2 hours, while 74% of patients had more than a 50% improvement. In one study, some patients saw a lift in their eyelids as fast as 5 minutes after the first dose! And many patients experience visible results as soon as 15 minutes after application.
In clinical trials, Upneeq® helped patients with acquired ptosis on the first day of treatment. 87.8% of patients had some form of improvement, while 40.8% of patients saw at least a 50% improvement on day 14 two hours after applying Upneeq®.
IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS
Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
DRUG INTERACTIONS
Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.